Quest Diagnostics sales and marketing update

Quest launched BRCAvantage Plus in the U.S. to screen for mutations in breast cancer 1 early onset (BRCA1), BRCA2, tumor protein p53 (TP53), phosphatase and tensin homolog deleted on chromosome te...